본문으로 건너뛰기
← 뒤로

Emerging Biomarkers for Managing Barrett's Esophagus.

1/5 보강
Gastrointestinal endoscopy clinics of North America 📖 저널 OA 10% 2024: 1/1 OA 2025: 0/2 OA 2026: 0/15 OA 2024~2026 2026 Vol.36(1) p. 149-170
Retraction 확인
출처

Rojanasopondist P, Kaz A, Yu M, Grady WM

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Comparative analyses of normal esophageal tissue, Barrett's Esophagus (BE), and esophageal adenocarcinoma have identified distinctive molecular alterations in genomic DNA, epigenetics, non-coding RNA,

이 논문을 인용하기

↓ .bib ↓ .ris
APA Rojanasopondist P, Kaz A, et al. (2026). Emerging Biomarkers for Managing Barrett's Esophagus.. Gastrointestinal endoscopy clinics of North America, 36(1), 149-170. https://doi.org/10.1016/j.giec.2025.05.005
MLA Rojanasopondist P, et al.. "Emerging Biomarkers for Managing Barrett's Esophagus.." Gastrointestinal endoscopy clinics of North America, vol. 36, no. 1, 2026, pp. 149-170.
PMID 41260765 ↗

Abstract

Comparative analyses of normal esophageal tissue, Barrett's Esophagus (BE), and esophageal adenocarcinoma have identified distinctive molecular alterations in genomic DNA, epigenetics, non-coding RNA, and proteins that have shown promise as disease-specific biomarkers. Some of the best characterized and promising biomarkers for managing BE are multi-target esophageal cytology DNA assays based on methylated-DNA and immunohistochemical staining of Trefoil factor 3. Additional biomarkers including microRNA, measures of genomic instability, mixed-method panels, and other novel biomarkers (e.g. volatile organic compounds and saliva microbiome) remain in early development and will need further validation in large, prospective studies prior to clinical use.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반